Non-opioid pain medication OK’d by FDA; Journavx could help blunt fentanyl addiction
Almost 1,200 people in Kern County have died from fentanyl overdoses since 2018, including 171 in 2024 and an all-time high of 294 the year before, according to updated numbers from the Kern County ...
verywellhealth21h
New FDA-Approved Painkiller Is a Safer Alternative to Opioids
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
Hosted on MSN1d
Blueberries To Green Beans: Fruits & Vegetables With Maximum Pesticide Content
According to WHO, pesticides are the leading cause of death by self-poisoning, particularly in low and middle income nations.
β-glucans show promise as adjuvants for allergy treatment
A recent study carried out by a research team from the Paul-Ehrlich-Institut investigated the immunomodulating properties of ...
FDA Approves First New Non-Opiod Painkiller in Decades
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
Nature1d
US drug agency approves potent painkiller — the first non-opioid in decades
The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
Frontiers1d
Combination Immune Therapies for the Treatment or Prevention of Breast or Gynecological Cancers
Recent advances in immunotherapy have revolutionized the treatment of breast and gynecological cancers, and current ...
FiercePharma2d
Sanofi's RSV antibody Beyfortus, after smashing blockbuster sales threshold, still has room to grow in US: execs
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
BioPharma Dive2d
Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...